Literature DB >> 28692951

Identifying critical steps towards improved access to innovation in cancer care: a European CanCer Organisation position paper.

Matti Aapro1, Alain Astier2, Riccardo Audisio3, Ian Banks4, Pierre Bedossa5, Etienne Brain6, David Cameron7, Paolo Casali8, Arturo Chiti9, Leticia De Mattos-Arruda10, Daniel Kelly11, Denis Lacombe12, Per J Nilsson13, Martine Piccart14, Philip Poortmans15, Katrine Riklund16, Gunnar Saeter17, Martin Schrappe18, Riccardo Soffietti19, Luzia Travado20, Hein van Poppel21, Suzanne Wait22, Peter Naredi23.   

Abstract

In recent decades cancer care has seen improvements in the speed and accuracy of diagnostic procedures; the effectiveness of surgery, radiation therapy and medical treatments; the power of information technology; and the development of multidisciplinary, specialist-led approaches to care. Such innovations are essential if we are to continue improving the lives of cancer patients across Europe despite financial pressures on our healthcare systems. Investment in innovation must be balanced with the need to ensure the sustainability of healthcare budgets, and all health professionals have a responsibility to help achieve this balance. It requires scrutiny of the way care is delivered; we must be ready to discontinue practices or interventions that are inefficient, and prioritise innovations that may deliver the best outcomes possible for patients within the limits of available resources. Decisions on innovations should take into account their long-term impact on patient outcomes and costs, not just their immediate costs. Adopting a culture of innovation requires a multidisciplinary team approach, with the patient at the centre and an integral part of the team. It must take a whole-system and whole-patient perspective on cancer care and be guided by high-quality real-world data, including outcomes relevant to the patient and actual costs of care; this accurately reflects the impact of any innovation in clinical practice. The European CanCer Organisation is committed to working with its member societies, patient organisations and the cancer community at large to find sustainable ways to identify and integrate the most meaningful innovations into all aspects of cancer care.
Copyright © 2017. Published by Elsevier Ltd.

Entities:  

Keywords:  Cancer; Clinical trial; Data collection; Efficiency; Healthcare systems; Innovation; Patient-relevant outcomes; Reimbursement; Value

Mesh:

Year:  2017        PMID: 28692951     DOI: 10.1016/j.ejca.2017.04.014

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  5 in total

Review 1.  New Frontiers for Fairer Breast Cancer Care in a Globalized World.

Authors:  Didier Verhoeven; Claudia Allemani; Cary Kaufman; Sabine Siesling; Manuela Joore; Etienne Brain; Mauricio Magalhães Costa
Journal:  Eur J Breast Health       Date:  2021-03-31

2.  Multidisciplinary teams and ICT: a qualitative study exploring the use of technology and its impact on multidisciplinary team meetings.

Authors:  Anna Janssen; Tracy Robinson; Melissa Brunner; Paul Harnett; Kylie E Museth; Tim Shaw
Journal:  BMC Health Serv Res       Date:  2018-06-13       Impact factor: 2.655

3.  From science to real-life oncology-the ECCO 2018 European Cancer Summit, 7-9 September 2018, Vienna, Austria.

Authors:  Sarah Liptrott
Journal:  Ecancermedicalscience       Date:  2018-10-15

Review 4.  Achieving equal and timely access to innovative anticancer drugs in the European Union (EU): summary of a multidisciplinary CECOG-driven roundtable discussion with a focus on Eastern and South-Eastern EU countries.

Authors:  Nils Wilking; Anna Bucsics; Lidlija Kandolf Sekulovic; Gisela Kobelt; Andrea Laslop; Lydia Makaroff; Alexander Roediger; Christoph Zielinski
Journal:  ESMO Open       Date:  2019-11-13

5.  Shifting cancer care towards Multidisciplinarity: the cancer center certification program of the German cancer society.

Authors:  Christoph Kowalski; Ullrich Graeven; Christof von Kalle; Hauke Lang; Matthias W Beckmann; Jens-Uwe Blohmer; Martin Burchardt; Michael Ehrenfeld; Jan Fichtner; Stephan Grabbe; Hans Hoffmann; Heinrich Iro; Stefan Post; Anton Scharl; Uwe Schlegel; Thomas Seufferlein; Walter Stummer; Dieter Ukena; Julia Ferencz; Simone Wesselmann
Journal:  BMC Cancer       Date:  2017-12-14       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.